(redirected from Myelosuppression)


(computer science)
Removal or deletion usually of insignificant digits in a number, especially zero suppression.
Optional function in either on-line or off-line printing devices that permits them to ignore certain characters or groups of characters which may be transmitted through them.
Elimination of any component of an emission, as a particular frequency or group of frequencies in an audio-frequency of a radio-frequency signal.



in genetics, a phenomenon that prevents the appearance of a character resulting from mutation and that causes partial or complete restoration of the normal phenotype.

Intragenic suppression is caused by a second (suppressor) mutation in the same gene in which the first (direct) mutation occurred. Intergenic suppression is caused by a second mutation in other genes that are located at a considerable distance from the suppressed gene. In intragenic suppression, a protein coded by a given gene can reacquire functional activity, although its original structure, in contrast to true reverse mutation, or reversion, is not restored. In intergenic suppression, the normal phenotype may be restored in some cases owing to mutations that permit other means of metabolism which do not require the functioning of the given gene. In other cases, the normal phenotype may be restored as a result of mutations that alter the process by which the genetic information of the mutant gene is realized.

The phenomenon of suppression, first discovered in 1920 by the American geneticist A. H. Sturtevant, is used to study the genetic code and other aspects of molecular genetics.


Stent, G. Molekuliarnaia genetika. Moscow, 1974. Chapter 6. (Translated from English.)


References in periodicals archive ?
In one patient series, IBD patients with impaired TPMT activity accounted for half of all cases of leukopenia and 27% of all cases of severe myelosuppression during 87 months of 6-MP or azathioprine therapy
Historically, dose limiting toxicity observed with VAL-083 was limited to myelosuppression.
One of the findings observed in clinical trials to date is the lack of myelosuppression seen with other treatments.